NCT00255827View on ClinicalTrials.gov

Vaccine Treatment for Surgically Resected Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 30, 2005

Study Completion Date

September 30, 2007

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

HyperAcute-Pancreatic Cancer Vaccine

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors
All Listed Sponsors
lead

NewLink Genetics Corporation

INDUSTRY

NCT00255827 - Vaccine Treatment for Surgically Resected Pancreatic Cancer | Biotech Hunter | Biotech Hunter